Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice

S. Pellegatta, P. L. Poliani, D. Corno, M. Grisoli, M. Cusimano, F. Ubiali, F. Baggi, M. G. Bruzzone, G. Finocchiaro

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In recent years, the use of dendritic cells (DC), the most powerful antigen presenting cells, has been proposed for the creation of vaccines against gliomas. This approach has been demonstrated to be safe and non-toxic in phase I or I-II trials (2, 3)2-5. Immunotherapy plays a central role in the search for new treatments for glioblastoma multiforme (GBM). In particular, several phase I studies have been performed using DC pulsed by GBM proteins as a vaccine for patients with relapsing GBM. The studies demonstrated that DC vaccination is safe and may produce a significant increase in overall survival. As the first step in the preparation of appropriate conditions for a clinical evaluation in Italy, we have performed pre-clinical experiments on immune-competent mice injected intra-cerebrally with syngeneic GL261 GBM cells and treated subcutaneously and intra-tumorally with DC loaaed with a GL261 homogenate. These results show that vaccination with DC pulsed with a tumor lysate increases considerably survival in mice bearing intracranial glioblastomas and supports the development of DC-based clinical trials for patients with glioblastomas that do not respond to standard therapies.

Original languageEnglish
Pages (from-to)527-531
Number of pages5
JournalNeurological Research
Volume28
Issue number5
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Glioblastoma
Glioma
Dendritic Cells
Immunity
Neoplasms
Vaccination
Vaccines
Survival
Antigen-Presenting Cells
Immunotherapy
Italy
Clinical Trials
Therapeutics
Proteins

Keywords

  • Dendritic cells
  • Glioma
  • Immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

@article{718379cfb5f74c0784a1ab31beeb1394,
title = "Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice",
abstract = "In recent years, the use of dendritic cells (DC), the most powerful antigen presenting cells, has been proposed for the creation of vaccines against gliomas. This approach has been demonstrated to be safe and non-toxic in phase I or I-II trials (2, 3)2-5. Immunotherapy plays a central role in the search for new treatments for glioblastoma multiforme (GBM). In particular, several phase I studies have been performed using DC pulsed by GBM proteins as a vaccine for patients with relapsing GBM. The studies demonstrated that DC vaccination is safe and may produce a significant increase in overall survival. As the first step in the preparation of appropriate conditions for a clinical evaluation in Italy, we have performed pre-clinical experiments on immune-competent mice injected intra-cerebrally with syngeneic GL261 GBM cells and treated subcutaneously and intra-tumorally with DC loaaed with a GL261 homogenate. These results show that vaccination with DC pulsed with a tumor lysate increases considerably survival in mice bearing intracranial glioblastomas and supports the development of DC-based clinical trials for patients with glioblastomas that do not respond to standard therapies.",
keywords = "Dendritic cells, Glioma, Immunotherapy",
author = "S. Pellegatta and Poliani, {P. L.} and D. Corno and M. Grisoli and M. Cusimano and F. Ubiali and F. Baggi and Bruzzone, {M. G.} and G. Finocchiaro",
year = "2006",
month = "7",
doi = "10.1179/016164106X116809",
language = "English",
volume = "28",
pages = "527--531",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "5",

}

TY - JOUR

T1 - Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice

AU - Pellegatta, S.

AU - Poliani, P. L.

AU - Corno, D.

AU - Grisoli, M.

AU - Cusimano, M.

AU - Ubiali, F.

AU - Baggi, F.

AU - Bruzzone, M. G.

AU - Finocchiaro, G.

PY - 2006/7

Y1 - 2006/7

N2 - In recent years, the use of dendritic cells (DC), the most powerful antigen presenting cells, has been proposed for the creation of vaccines against gliomas. This approach has been demonstrated to be safe and non-toxic in phase I or I-II trials (2, 3)2-5. Immunotherapy plays a central role in the search for new treatments for glioblastoma multiforme (GBM). In particular, several phase I studies have been performed using DC pulsed by GBM proteins as a vaccine for patients with relapsing GBM. The studies demonstrated that DC vaccination is safe and may produce a significant increase in overall survival. As the first step in the preparation of appropriate conditions for a clinical evaluation in Italy, we have performed pre-clinical experiments on immune-competent mice injected intra-cerebrally with syngeneic GL261 GBM cells and treated subcutaneously and intra-tumorally with DC loaaed with a GL261 homogenate. These results show that vaccination with DC pulsed with a tumor lysate increases considerably survival in mice bearing intracranial glioblastomas and supports the development of DC-based clinical trials for patients with glioblastomas that do not respond to standard therapies.

AB - In recent years, the use of dendritic cells (DC), the most powerful antigen presenting cells, has been proposed for the creation of vaccines against gliomas. This approach has been demonstrated to be safe and non-toxic in phase I or I-II trials (2, 3)2-5. Immunotherapy plays a central role in the search for new treatments for glioblastoma multiforme (GBM). In particular, several phase I studies have been performed using DC pulsed by GBM proteins as a vaccine for patients with relapsing GBM. The studies demonstrated that DC vaccination is safe and may produce a significant increase in overall survival. As the first step in the preparation of appropriate conditions for a clinical evaluation in Italy, we have performed pre-clinical experiments on immune-competent mice injected intra-cerebrally with syngeneic GL261 GBM cells and treated subcutaneously and intra-tumorally with DC loaaed with a GL261 homogenate. These results show that vaccination with DC pulsed with a tumor lysate increases considerably survival in mice bearing intracranial glioblastomas and supports the development of DC-based clinical trials for patients with glioblastomas that do not respond to standard therapies.

KW - Dendritic cells

KW - Glioma

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33746512540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746512540&partnerID=8YFLogxK

U2 - 10.1179/016164106X116809

DO - 10.1179/016164106X116809

M3 - Article

C2 - 16808884

AN - SCOPUS:33746512540

VL - 28

SP - 527

EP - 531

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 5

ER -